(Q34743306)

4 August 2017

1 reference

title

Ethical perspectives on pharmacogenomic profiling in the drug development process (English)

1 reference

4 August 2017

0 references

ethical review process

0 references

1 reference

Amalia M Issa

1

1 reference

4 August 2017

publication date

1 April 2002

1 reference

Nature Reviews Drug Discovery

4 August 2017

published in

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

300-308

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

4 August 2017

cites work

1 reference

Pharmacogenomics: unlocking the human genome for better drug therapy

21 January 2018

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

Genetic susceptibility to adverse drug reactions

21 January 2018

1 reference

Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience

21 January 2018

1 reference

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma

21 January 2018

1 reference

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

APOE genotyping and response to drug treatment in Alzheimer's disease

21 January 2018

1 reference

The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.

21 January 2018

1 reference

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

Consent and privacy in pharmacogenetic testing.

21 January 2018

1 reference

Ethical considerations in clinical pharmacogenomics research

21 January 2018

1 reference

What makes clinical research ethical?

21 January 2018

1 reference

Pharmacogenomics: the genomics of drug response

21 January 2018

1 reference

Case-control association studies for the genetics of complex respiratory diseases

21 January 2018

1 reference

Genetic association studies: genes in search of diseases

21 January 2018

1 reference

The genetic basis of variability in drug responses

21 January 2018

1 reference

The use of single-nucleotide polymorphism maps in pharmacogenomics

21 January 2018

1 reference

Alpha-2 macroglobulin is genetically associated with Alzheimer disease

21 January 2018

1 reference

Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK.

21 January 2018

1 reference

Alpha-2 macroglobulin gene and Alzheimer disease.

21 January 2018

1 reference

An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease.

21 January 2018

1 reference

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

21 January 2018

1 reference

Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues

21 January 2018

1 reference

Sifting the evidence-what's wrong with significance tests?

21 January 2018

1 reference

Uneasy alliance--clinical investigators and the pharmaceutical industry

21 January 2018

1 reference

Linkage disequilibrium and the search for complex disease genes

21 January 2018

1 reference

Association study designs for complex diseases

21 January 2018

1 reference

Academic relationships with industry: a new model for biomedical research.

21 January 2018

1 reference

Interactions between genes and environment in the development of asthma

21 January 2018

1 reference

Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

21 January 2018

1 reference

Epidemiology set to get fast-track treatment

21 January 2018

1 reference

Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications

21 January 2018

1 reference

Clinical pharmacogenomics: applications in pharmaceutical R&D

31 March 2020

1 reference

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality

31 March 2020

1 reference

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

31 March 2020

1 reference

Association between clozapine response and allelic variation in 5-HT2A receptor gene

31 March 2020

1 reference

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

31 March 2020

1 reference

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial

31 March 2020

1 reference

Testing drug response in the presence of genetic information: sampling issues for clinical trials

31 March 2020

1 reference

31 March 2020

1 reference

Participation in clinical trials and long-term outcomes in Alzheimer's disease

31 March 2020

1 reference

Family-based association studies

31 March 2020

1 reference

Inventing the pharmacogenomics business

31 March 2020

1 reference

The business of pharmacogenomics

31 March 2020

1 reference

Interpretation of results from genetic studies of multifactorial diseases

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD771

1 reference

4 August 2017

1 reference